Biochemistry Section, Faculty of Sciences and Chemical Technologies, University of Castilla-La Mancha, Avda. Camilo José Cela 10, 13071 Ciudad Real, Spain.
Molecular Regulation of Heart Failure Research Group, National Cardiovascular Research Center Carlos III (CNIC), Melchor Fernández Almagro 3, 28029 Madrid, Spain.
Biomolecules. 2024 Aug 18;14(8):1028. doi: 10.3390/biom14081028.
Leptin, acting centrally or peripherally, has complex effects on cardiac remodeling and heart function. We previously reported that central leptin exerts an anti-hypertrophic effect in the heart via cardiac PPARβ/δ activation. Here, we assessed the impact of central leptin administration and PPARβ/δ inhibition on cardiac function. Various cardiac properties, including QRS duration, R wave amplitude, heart rate (HR), ejection fraction (EF), end-diastolic left ventricular mass (EDLVM), end-diastolic volume (EDV), and cardiac output (CO) were analyzed. Central leptin infusion increased cardiac PPARβ/δ protein content and decreased HR, QRS duration, and R wave amplitude. These changes induced by central leptin suggested a decrease in the ventricular wall growth, which was confirmed by MRI. In fact, the EDLVM was reduced by central leptin while increased in rats co-treated with leptin and GSK0660, a selective antagonist of PPARβ/δ activity. In summary, central leptin plays a dual role in cardiac health, potentially leading to ventricular atrophy and improving heart function when PPARβ/δ signaling is intact. The protective effects of leptin are lost by PPARβ/δ inhibition, underscoring the importance of this pathway. These findings highlight the therapeutic potential of targeting leptin and PPARβ/δ pathways to combat cardiac alterations and heart failure, particularly in the context of obesity.
瘦素通过中枢或外周作用,对心脏重构和心功能具有复杂影响。我们之前曾报道,中枢瘦素通过心脏 PPARβ/δ 的激活发挥抗心肌肥厚作用。在此,我们评估了中枢瘦素给药和 PPARβ/δ 抑制对心脏功能的影响。分析了各种心脏特性,包括 QRS 持续时间、R 波幅度、心率(HR)、射血分数(EF)、舒张末期左心室质量(EDLVM)、舒张末期容积(EDV)和心输出量(CO)。中枢瘦素输注增加了心脏 PPARβ/δ 蛋白含量,降低了 HR、QRS 持续时间和 R 波幅度。这些由中枢瘦素引起的变化表明心室壁生长减少,这通过 MRI 得到了证实。事实上,中枢瘦素使 EDLVM 减少,而在同时给予瘦素和 GSK0660(PPARβ/δ 活性的选择性拮抗剂)的大鼠中则增加。总之,中枢瘦素在心脏健康中发挥双重作用,当 PPARβ/δ 信号完好时,可能导致心室萎缩并改善心功能。PPARβ/δ 抑制会使瘦素的保护作用丧失,这凸显了该途径的重要性。这些发现强调了靶向瘦素和 PPARβ/δ 途径以对抗心脏改变和心力衰竭的治疗潜力,特别是在肥胖的背景下。